Skip to main content

LeonaBio, Inc.

corporate_fare Company Profile

LeonaBio, Inc.

LONA·NASDAQ·Life Sciences·CIK 0001620463

LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing new treatments for significant unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). In December 2025, the company acquired rights to lasofoxifene, a late-stage asset for the potential treatment of ESR1-mutated (mESR1) metastatic breast cancer. This program has generated promising clinical data. LeonaBio, Inc. also has an in-house asset, ATH-1105, which is a Phase 2-ready program for the potential treatment of ALS. The company aims to advance a pipeline of innovative, late-stage assets, both internally developed and strategically in-licensed. LeonaBio, Inc.'s lead drug candidates are lasofoxifene and ATH-1105, which are novel, small molecule therapies. Lasofoxifene, a selective estrogen receptor modulator (SERM), is currently being evaluated in an ongoing registrational Phase 3 trial for metastatic breast cancer with ESR1 mutations. ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, has completed a first-in-human Phase 1 trial, and planning for a Phase 2 clinical trial for the treatment of ALS is underway. These programs target unmet needs in either oncology or neurology.

LeonaBio, Inc. (NASDAQ:LONA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for LONA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Shareholders to Vote on Highly Dilutive Warrant Exercises, New Equity Plan, and Massive Authorized Share Increase
  • LeonaBio Shareholders to Vote on Critical Dilution Proposals and Expanded Equity Plan
  • LeonaBio Registers 5.5M Shares for Resale by Strategic Partner, Creating Significant Share Overhang
  • LeonaBio Registers Resale of 58.4M Shares by Selling Stockholders, Signaling Massive Potential Dilution
  • LeonaBio Discloses Highly Dilutive Private Placement, More Than Doubling Shares Outstanding

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$105.61M
Diluted EPS
-$24.70
Op. Cash Flow
-$45.73M
Operating Income
-$102.27M
Cash & Equivalents
$69.28M
Debt / Equity
0.00×
Shares Outstanding
9.34M sh
Source: 10-K · filed 2026-03-31 · accession 0001193125-26-134565
$2.01 -0.50% today
52-week range · as of 2026-11-16 $2.01 – $14.21
Market cap
$26.41M
Volume
68.9K (1.0× avg)
3-mo avg 71.6K
Live data · 2026-11-21 22:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LONA - Filings & News (Page 2)

LONA
Feb 23, 2026, 4:05 PM EST
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $5.80
Real-time Price: $2.01 info
Change: -$3.79 (-65%) info
Market Cap: $26.414M info
LONA
Feb 04, 2026, 4:53 PM EST
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $4.72
Real-time Price: $2.01 info
Change: -$2.71 (-57%) info
Market Cap: $26.414M info
LONA
Jan 20, 2026, 4:42 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $6.21
Real-time Price: $2.01 info
Change: -$4.20 (-68%) info
Market Cap: $26.414M info
LONA
Jan 20, 2026, 4:24 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $6.21
Real-time Price: $2.01 info
Change: -$4.20 (-68%) info
Market Cap: $26.414M info
LONA
Jan 16, 2026, 4:46 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $6.01
Real-time Price: $2.01 info
Change: -$4.00 (-67%) info
Market Cap: $26.414M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets